artnet AG

  • WKN: A1K037
  • ISIN: DE000A1K0375
  • Land: Deutschland

Nachricht vom 31.08.2021 | 02:25

artnet AG: Annual General Meeting on September 29, 2021, postponed

artnet AG / Key word(s): AGM/EGM
artnet AG: Annual General Meeting on September 29, 2021, postponed

31-Aug-2021 / 02:25 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The Annual General Meeting of artnet AG convened for Wednesday, September 29, 2021, 10:00 a.m. CEST by publication in the German Federal Gazette (Bundesanzeiger) on August 20, 2021, is hereby postponed. The invitation to the Annual General Meeting published in the German Federal Gazette on August 20, 2021, is therefore invalid.

By postponing the Annual General Meeting, the sole member of the Management Board (Vorstand) of artnet AG would like to facilitate discussions with significant shareholders -such as Weng Fine Art AG and Galerie Neuendorf AG- on individual agenda items in order to achieve the broadest possible support for all agenda items in the interests of the Company and all shareholders. The new date for the Annual General Meeting will be announced in due course.

Moritz Bauer

31-Aug-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

01. Dezember 2021